Full-Time

Toxicologic Pathology Externship

Posted on 1/15/2025

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops medicines for serious diseases

Biotechnology
Healthcare

Entry

Tarrytown, NY, USA

Paid externship; housing is not provided.

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • Currently a resident in an anatomic pathology training program or a Veterinary Pathology fellow who has previously completed a pathology residency
  • Experience in evaluating diagnostic case material
  • Self-motivated with a clear and demonstrable interest in anatomic pathology, particularly histopathology
  • Experience in pathology and a demonstrable interest in toxicologic pathology
Responsibilities
  • Microscopic pathology experience with a variety of strains of rodents (mice and rats)
  • Experience with digital pathology and image analysis in the context of discovery and preclinical safety assessment
  • A preview of the activities of a toxicologic pathologist in a pharmaceutical company
  • Access to transgenic rodents
Desired Qualifications
  • Highly motivated fourth-year veterinary student with experience in pathology and a demonstrable interest in toxicologic pathology
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its development efforts. Unlike many competitors, Regeneron focuses on both research and commercialization, generating revenue through the sale of its approved medicines and licensing its technologies. The goal of Regeneron is to improve patient outcomes by providing effective treatments and ensuring that its products meet high safety and efficacy standards.

Company Stage

IPO

Total Funding

$684M

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Regeneron's investment in Truveta enhances its genomic data capabilities for personalized medicine.
  • The Oxular acquisition expands Regeneron's portfolio in retinal disorder treatments.
  • Dupixent's FDA review for CSU could open a new revenue stream for Regeneron.

What critics are saying

  • Class action lawsuits may lead to financial liabilities and reputational damage.
  • Investment in Truveta may not yield expected financial returns.
  • Competition from AstraZeneca and Amgen could impact Regeneron's market share.

What makes Regeneron Pharmaceuticals unique

  • Regeneron leverages proprietary technologies for innovative treatments in serious diseases.
  • The company collaborates with academic and research institutions to enhance R&D efforts.
  • Regeneron's strategic partnerships enable shared costs and profits in new treatment development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours